Basic Stock Data on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

In the past 52-week period, shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) have moved within the range of $20.68 to $41.20. On the stock’s most recent trading day, the company’s shares ended the regular session at $35.64, which is 13.5% lower than its 52-week high.

ACADIA Pharmaceuticals Inc. (ACAD) has demonstrated a 20-day simple moving average (SMA) of -4.14%, and a 50-day SMA of -0.18%. This public company’s current market capitalization stands at $4.30 billion.

Analyzing Consensus Estimates, Sales Revenue and Net Income

Understanding Wall Street analyst’s enthusiasm for a particular stock is crucial when considering entering a position. According to the latest data, the consensus recommendation for ACADIA Pharmaceuticals Inc. (ACAD) is Outperform.

When it comes to sales data, public companies usually post revenue and earnings that are either higher or lower than the average Wall Street forecast. In the most recent quarterly financial report, for the quarter ending Jun. 2017, ACADIA Pharmaceuticals Inc. (ACAD) delivered a 52.24% surprise with its net revenue. Sales reached $0.03 billion during the three-month period, compared to the average analyst estimate of $0.02 billion.

Meanwhile, during the same quarter ACADIA Pharmaceuticals Inc. (ACAD) delivered a -23.61% earnings surprise. Net earnings for the quarter were posted at -$0.55 per share, whereas Wall Street had forecast -$0.72 per share.

Ownership at ACADIA Pharmaceuticals Inc. (ACAD), According to Most Recent SEC Filings

A public company’s latest 13F filings tell investors important details about institutional ownership. ACADIA Pharmaceuticals Inc. (ACAD) has 0.12 billion shares outstanding currently, 101.09% of which belong to institutional investors. Those institutional holdings amount to $4.43 billion.

Additionally, according to the most recent 13F filing from ACADIA Pharmaceuticals Inc. (ACAD), there were 23 new positions totaling 4,625,546 shares of the company’s stock. There were 34 sold out positions, on the other hand, totaling 3,145,581 shares.